Regulus Therapeutics (NASDAQ:RGLS)

CAPS Rating: 2 out of 5

RGLS News and Commentary

Caps

How do you think RGLS will perform against the market?

Add Stock to CAPS Watchlist

All Players

28 Outperform
15 Underperform
 

All-Star Players

13 Outperform
4 Underperform
 

Wall Street

0 Outperform
2 Underperform
 

Top RGLS Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.83)
Submitted February 03, 2015

I could spend about six hours analyzing the prospects of RG-101 in the hepatitis C market and then correlating this with Regulus's current market cap, but honestly I'm 70% sure I'd end up with a negative opinion. The reason I own 550 shares of… More

zzlangerhans (99.83)
Submitted April 04, 2013

It would have been nice to get this at yesterday's close of 7.4 but I still think Regulus is overpriced at 6.8. They have an enterprise value of 150M and all they have to justify it is their Isis/Alnylam pedigree. They won't be submitting an IND for… More

RGLS VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about RGLS.

Recs

0
Member Avatar oscillation (78.57) Submitted: 2/25/2017 12:11:02 PM : Outperform Start Price: $1.05 RGLS Score: +6.59

nev

Recs

5
Member Avatar zzlangerhans (99.83) Submitted: 2/3/2015 1:19:42 AM : Outperform Start Price: $17.78 RGLS Score: -122.40

I could spend about six hours analyzing the prospects of RG-101 in the hepatitis C market and then correlating this with Regulus's current market cap, but honestly I'm 70% sure I'd end up with a negative opinion. The reason I own 550 shares of Regulus with cost basis 15.56 is that on October 7 of last year I was on a month-long road trip in Europe with my family when Portefeuille requested that I buy 1500 shares which I executed at 6.73. Two weeks later the company reported viral load reduction data from a phase I trial of RG-101 that caused the stock to rise more than 100%. Our current gains stand at $13000, most of which has been realized in completed sales. Between the Regulus play and another winning bet he suggested while I was completely oblivious to the market, the entire trip was paid for. At the time, I completely forgot to enter a CAPS outperform on Regulus which is why I'm not currently sitting on a 150 point gain there. I'm remedying that oversight now. What will happen when Regulus reports viral load reduction data from a higher dose cohort of RG-101 sometime in the next ten days? I'm really not sure, but I'd have to be a complete idiot not to go with Portefeuille's instructions this time round.

Recs

0
Member Avatar rknapton (20.74) Submitted: 8/22/2013 4:56:09 PM : Underperform Start Price: $9.51 RGLS Score: +141.65

Short. Biotech. High P/S ratio.

Leaderboard

Find the members with the highest scoring picks in RGLS.

Score Leader

mistermiranga

mistermiranga (99.69) Score: +174.24

I own zzlangerhans in biopharma trading. I also dominate his little German partner Schulz!

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
HDTVBGII 69.67 11/9/2012 Underperform 3W $4.75 -74.53% +84.56% +159.09 0 Comment
ta2122 34.79 10/8/2012 Underperform 5Y $4.50 -73.11% +76.59% +149.70 0 Comment
KidJones 30.32 4/12/2013 Underperform 5Y $6.73 -82.02% +62.03% +144.05 0 Comment
rknapton 20.74 8/23/2013 Underperform 5Y $9.51 -87.28% +54.37% +141.65 1 Comment
DfenceCtr 48.85 7/17/2013 Underperform 3Y $10.19 -88.13% +52.90% +141.02 0 Comment
thebeef41 42.54 9/30/2013 Underperform 1Y $9.09 -86.69% +53.52% +140.21 0 Comment
ACMGresearch 47.06 5/10/2013 Underperform 5Y $6.89 -82.44% +57.75% +140.18 0 Comment
pro64grammer 28.77 10/22/2014 Underperform 5Y $14.61 -91.72% +32.74% +124.45 0 Comment
kjh133 64.35 10/22/2014 Underperform 3M $12.85 -90.58% +32.36% +122.94 0 Comment
joe508mama 32.54 10/22/2014 Underperform 5Y $12.57 -90.37% +32.24% +122.61 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackUltraLong < 20 4/29/2013 Underperform NS $6.87 -82.39% +62.04% +144.43 1 Comment
TrackJimCramer 84.96 10/15/2012 Underperform 3W $4.24 -71.46% +78.45% +149.91 0 Comment

Featured Broker Partners